Comment on Herring et al. The Use of “Retardation” in FRAXA, FMRP, FMR1 and Other Designations. Cells 2022, 11, 1044

This commentary is written in response to the recent article from Herring et al., discussing the eradication of the offensive term “retardation” from gene nomenclature. We discuss the work of the HUGO (Human Genome Organisation) Gene Nomenclature Committee (HGNC) and outline the steps already taken...

Descripción completa

Detalles Bibliográficos
Autor principal: Bruford, Elspeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221639/
https://www.ncbi.nlm.nih.gov/pubmed/35741066
http://dx.doi.org/10.3390/cells11121937
_version_ 1784732672362283008
author Bruford, Elspeth
author_facet Bruford, Elspeth
author_sort Bruford, Elspeth
collection PubMed
description This commentary is written in response to the recent article from Herring et al., discussing the eradication of the offensive term “retardation” from gene nomenclature. We discuss the work of the HUGO (Human Genome Organisation) Gene Nomenclature Committee (HGNC) and outline the steps already taken to remove this term from our gene names. We also highlight the latest nomenclature changes made as a result of discussions with the authors and agreement with the European Fragile X Network.
format Online
Article
Text
id pubmed-9221639
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92216392022-06-24 Comment on Herring et al. The Use of “Retardation” in FRAXA, FMRP, FMR1 and Other Designations. Cells 2022, 11, 1044 Bruford, Elspeth Cells Comment This commentary is written in response to the recent article from Herring et al., discussing the eradication of the offensive term “retardation” from gene nomenclature. We discuss the work of the HUGO (Human Genome Organisation) Gene Nomenclature Committee (HGNC) and outline the steps already taken to remove this term from our gene names. We also highlight the latest nomenclature changes made as a result of discussions with the authors and agreement with the European Fragile X Network. MDPI 2022-06-16 /pmc/articles/PMC9221639/ /pubmed/35741066 http://dx.doi.org/10.3390/cells11121937 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Comment
Bruford, Elspeth
Comment on Herring et al. The Use of “Retardation” in FRAXA, FMRP, FMR1 and Other Designations. Cells 2022, 11, 1044
title Comment on Herring et al. The Use of “Retardation” in FRAXA, FMRP, FMR1 and Other Designations. Cells 2022, 11, 1044
title_full Comment on Herring et al. The Use of “Retardation” in FRAXA, FMRP, FMR1 and Other Designations. Cells 2022, 11, 1044
title_fullStr Comment on Herring et al. The Use of “Retardation” in FRAXA, FMRP, FMR1 and Other Designations. Cells 2022, 11, 1044
title_full_unstemmed Comment on Herring et al. The Use of “Retardation” in FRAXA, FMRP, FMR1 and Other Designations. Cells 2022, 11, 1044
title_short Comment on Herring et al. The Use of “Retardation” in FRAXA, FMRP, FMR1 and Other Designations. Cells 2022, 11, 1044
title_sort comment on herring et al. the use of “retardation” in fraxa, fmrp, fmr1 and other designations. cells 2022, 11, 1044
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221639/
https://www.ncbi.nlm.nih.gov/pubmed/35741066
http://dx.doi.org/10.3390/cells11121937
work_keys_str_mv AT brufordelspeth commentonherringetaltheuseofretardationinfraxafmrpfmr1andotherdesignationscells2022111044
AT commentonherringetaltheuseofretardationinfraxafmrpfmr1andotherdesignationscells2022111044

Ejemplares similares